The Catalyst

Most Recent Posts

05.06.11 | By Kate Connors

A recent study in the Journal of the American Medical Association raises notable points about the current presence of comparative effectiveness research (CER) in the health care system.

Excluding orphan drugs and first-in-class medicines, a majority of new medicines (defined as new molecular entities) approved by the FDA between 2000 and 2010 had CER data available at the time of approval.

05.05.11 | By Kate Connors

Andrew Sullivan, in The Daily Beast, directed my attention to an opinion piece on The New York Times's Opinionator blog about "the science gap" - in other words, how evolving science is changing the research landscape. Sullivan featured a quote from Stanford University's Dr.

05.05.11

With the debate over the future of Medicare heating up, there are two interesting recent opinion pieces worth taking a look at.

The first by Former HHS Secretary and Governor of Wisconsin Tommy Thompson and Donald Crand, President & CEO of the California Association of Physician Groups (CAPG) in the Huffington Post.

05.04.11 | By Kate Connors

An article in today's Boston Globe refers to biopharmaceutical research companies "dedicating more resources to rare disorders, illnesses that are prevalent in the developing world, and medical conditions that affect minority populations in rich countries."

05.03.11

The devastation caused by the string of tornadoes and storms continues to be felt. We've already blogged a couple of times on what Rx Response is doing to assist state and local emergency managers. But circumstances call for additional help for many of the region's uninsured patients, and the Partnership for Prescription Assistance is also stepping in to help.

05.03.11 | By Kate Connors

For years, PhRMA has supported several programs that educate consumers about the safe disposal of expired and unused medications, including SMARxT Disposal, American Medicine Chest Challenge, and most recently, the DEA National Take Back Day, which occurred April 30 at approved locations across the nation.

05.02.11 | By Erin Mullen

As a result of the string of deadly tornadoes that have ravaged the Southeast United States, Rx Response began immediately monitoring the storms' impact on the flow of medicine in the affected areas and has elevated its engagement status from Stand-By to Alert.

04.29.11

Responding to the wave of storms and storm-related damage and injuries across the Southern United States, Rx Response, as part of its situation monitoring effort, has initiated Pharmacy Status Reporting within the following states affected by the severe tornadoes in the southeast:

04.29.11 | By Kate Connors

Walmart, the nation's largest retailer, recently joined SMARxT Disposal, a program that helps educate customers about the proper way to quickly and safely dispose of any unused prescription drugs. Walmart will launch the national educational program in more than 3,500 of their pharmacies.

04.29.11

Douglas Peddicord, Ph.D., has an interesting blog post on the high quality of clinical trials conducted around the world in the Huffington Post.

04.28.11 | By Kate Connors

Two weeks ago at our annual meeting, attendees heard a variety of governors talk about the roles that biopharmaceutical research companies play in their state economies. Now, a new resource on PhRMA's website makes it easier for the public to see this role.

04.28.11

The Huffington Post has an interesting piece today that's worth reading on new efforts to research and develop new medicines to treat rare diseases. Of course, many of these efforts aren't really new. America's biopharmaceutical research companies have long researched and developed medicines targeting rare diseases (i.e. conditions affecting less than 200,000 patients).

04.26.11 | By Kate Connors

A few weeks ago, the indomitable Jennifer Windrum, of WTF: Where's The Funding? (for lung cancer), asked me to write a guest post for her blog. I was honored, and saw it as a great opportunity to reach cancer patients who may not know just how much work is going into research and development for new medicines to potentially treat the countless cancers that plague so many Americans.

04.26.11 | By Kate Connors

Sunday's Boston Globe included a multi-part series detailing Cambridge, Mass.-based Vertex Pharmaceuticals, Inc., a growing biopharmaceutical firm that is hoping to find itself on the cusp of moving from a young start-up to a commercially viable company. In this sense, it's a great example of the many emerging companies that contribute to the work done throughout the biopharmaceutical research sector, and we'll continue to highlight similar emerging companies in the future here on The Catalyst.

04.26.11

Kate and I talk about innovation a lot. We talk about science and the process of discovery. We talk about the cost of researching and discovering new medicines. And, we talk about the new medicines and their long road from laboratory to approval for patient use.

Pages